NanoSyrinx is a discovery stage biotechnology company based at the University of Warwick’s Medical School.
NanoSyrinx is an emerging biotechnology company developing a novel system for targeted delivery of therapeutic proteins and peptides direct to the cytosol. We are using synthetic biology approaches to develop a completely novel method for targeted drug delivery of therapeutic proteins and peptides, to the interiors of cells, to improve efficacy, safety, and economy.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Jul 19, 2021 | Seed | £6.20M | 1 | Octopus Ventures | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Octopus Ventures | Yes | Seed |